Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vaxcyte, Inc.PCVX · Entity 1164 | SVP, GEN COUNSEL & CORP SEC | March 05, 2025 | March 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vaxcyte, Inc.
Report date March 05, 2025 · Filed March 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,620 |
Ending reported balance
After 2025-03-05 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2025-03-05 · Exercise / conversion · Acquired 5,000 · Balance 46,620 Row 2 · 2025-03-05 · Sale · Disposed 2,621 · Balance 43,999 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $69.745 to $70.735. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 3 · 2025-03-05 · Sale · Disposed 2,267 · Balance 41,732 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $70.745 to $71.62. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 4 · 2025-03-05 · Sale · Disposed 112 · Balance 41,620 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.41 · Expires 2032-05-08 | Direct | 144,497 |
Reported balance
After 2025-03-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-03-05 · Exercise / conversion · Disposed 5,000 · Balance 144,497 F4: 1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024.
F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $69.745 to $70.735. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $70.745 to $71.62. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: 1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2025 Filed Mar 7, 2025 21:43 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $21.41 | $0.00 |
DisclosureSEC source: 0001649094-25-000045 · wk-form4_1741383777.xml · derivative · entry 5 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,497 Underlying: Common Stock · 5,000 shares Expires 2032-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:43 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 112 | $72.37 | $8,105.44 |
DisclosureSEC source: 0001649094-25-000045 · wk-form4_1741383777.xml · nonDerivative · entry 4 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,620 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:43 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,267 | $71.07 | $161,106.62 |
DisclosureSEC source: 0001649094-25-000045 · wk-form4_1741383777.xml · nonDerivative · entry 3 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,732 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $70.745 to $71.62. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:43 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,621 | $70.39 | $184,486.95 |
DisclosureSEC source: 0001649094-25-000045 · wk-form4_1741383777.xml · nonDerivative · entry 2 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,999 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $69.745 to $70.735. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:43 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 5,000 | $21.41 | $107,050.00 |
DisclosureSEC source: 0001649094-25-000045 · wk-form4_1741383777.xml · nonDerivative · entry 1 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 02:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 616 | $72.10 | $44,413.60 |
DisclosureSEC source: 0001649094-25-000040 · wk-form4_1741054520.xml · nonDerivative · entry 3 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,620 F2 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 02:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 470 | $73.02 | $34,319.40 |
DisclosureSEC source: 0001649094-25-000040 · wk-form4_1741054520.xml · nonDerivative · entry 2 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,236 F2 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 02:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 48,357 | $0.00 Strike: $74.22 | $0.00 |
DisclosureSEC source: 0001649094-25-000040 · wk-form4_1741054520.xml · derivative · entry 4 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,357 Underlying: Common Stock · 48,357 shares Expires 2035-02-26 F3 · derivative.exercise_date: 1/48 of shares subject to the option vest on March 27, 2025, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 02:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 14,484 | $0.00 | $0.00 |
DisclosureSEC source: 0001649094-25-000040 · wk-form4_1741054520.xml · nonDerivative · entry 1 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,706 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 7, 2025 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:04 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $21.41 | $0.00 |
DisclosureSEC source: 0001649094-25-000012 · wk-form4_1738962245.xml · derivative · entry 7 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,497 Underlying: Common Stock · 5,000 shares Expires 2032-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:04 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 255 | $91.71 | $23,385.54 |
DisclosureSEC source: 0001649094-25-000012 · wk-form4_1738962245.xml · nonDerivative · entry 6 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,222 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F6 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $91.69 to $91.71. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:04 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,784 | $91.05 | $162,436.77 |
DisclosureSEC source: 0001649094-25-000012 · wk-form4_1738962245.xml · nonDerivative · entry 5 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,477 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $90.66 to $91.585. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:04 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,755 | $89.95 | $157,860.50 |
DisclosureSEC source: 0001649094-25-000012 · wk-form4_1738962245.xml · nonDerivative · entry 4 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,261 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $89.53 to $90.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:04 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 635 | $89.09 | $56,570.88 |
DisclosureSEC source: 0001649094-25-000012 · wk-form4_1738962245.xml · nonDerivative · entry 3 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,016 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $88.52 to $89.385. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:04 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 571 | $87.77 | $50,114.96 |
DisclosureSEC source: 0001649094-25-000012 · wk-form4_1738962245.xml · nonDerivative · entry 2 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,651 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $87.405 to $88.36. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:04 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 5,000 | $21.41 | $107,050.00 |
DisclosureSEC source: 0001649094-25-000012 · wk-form4_1738962245.xml · nonDerivative · entry 1 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 21:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $21.41 | $0.00 |
DisclosureSEC source: 0001649094-25-000004 · wk-form4_1736285608.xml · derivative · entry 5 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,497 Underlying: Common Stock · 5,000 shares Expires 2032-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 21:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 125 | $86.52 | $10,815.00 |
DisclosureSEC source: 0001649094-25-000004 · wk-form4_1736285608.xml · nonDerivative · entry 4 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,222 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 21:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,921 | $85.73 | $336,155.17 |
DisclosureSEC source: 0001649094-25-000004 · wk-form4_1736285608.xml · nonDerivative · entry 3 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,347 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F3 · shares: The price reported is a weighted-average price. The shares were sold at prices ranging from $85.235 to $86.23. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 21:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 954 | $84.86 | $80,952.62 |
DisclosureSEC source: 0001649094-25-000004 · wk-form4_1736285608.xml · nonDerivative · entry 2 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,268 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F2 · shares: The price reported is a weighted-average price. The shares were sold at prices ranging from $84.23 to $85.17. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 21:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 5,000 | $21.41 | $107,050.00 |
DisclosureSEC source: 0001649094-25-000004 · wk-form4_1736285608.xml · nonDerivative · entry 1 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2024 Filed Dec 9, 2024 23:28 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 475 | $92.06 | $43,728.50 |
DisclosureSEC source: 0001649094-24-000118 · wk-form4_1733786878.xml · nonDerivative · entry 6 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,222 F7 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. Read SEC document |
| December 05, 2024 Filed Dec 9, 2024 23:28 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $21.41 | $0.00 |
DisclosureSEC source: 0001649094-24-000118 · wk-form4_1733786878.xml · derivative · entry 7 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,497 Underlying: Common Stock · 5,000 shares Expires 2032-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. Read SEC document |
| December 05, 2024 Filed Dec 9, 2024 23:28 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 388 | $92.90 | $36,045.59 |
DisclosureSEC source: 0001649094-24-000118 · wk-form4_1733786878.xml · nonDerivative · entry 5 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,697 F3 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F6 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $92.29 to $93.11. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 05, 2024 Filed Dec 9, 2024 23:28 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,177 | $91.91 | $292,004.42 |
DisclosureSEC source: 0001649094-24-000118 · wk-form4_1733786878.xml · nonDerivative · entry 4 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,085 F3 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $91.265 to $92.175. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 05, 2024 Filed Dec 9, 2024 23:28 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,435 | $90.16 | $129,383.91 |
DisclosureSEC source: 0001649094-24-000118 · wk-form4_1733786878.xml · nonDerivative · entry 3 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,262 F3 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $89.655 to $90.645. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 05, 2024 Filed Dec 9, 2024 23:28 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 5,000 | $21.41 | $107,050.00 |
DisclosureSEC source: 0001649094-24-000118 · wk-form4_1733786878.xml · nonDerivative · entry 2 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2024 Filed Dec 9, 2024 23:28 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GiftCommon Stock | 110 | $0.00 | $0.00 |
DisclosureSEC source: 0001649094-24-000118 · wk-form4_1733786878.xml · nonDerivative · entry 1 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,697 F1 · shares: Represents a bona fide gift of the Issuer's Common Stock to a non-profit educational institution. F2 · balance_after: Includes 184 shares acquired on November 15, 2024 under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:50 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantPerformance Stock Option (right to buy) · Derivative | 26,125 | $0.00 Strike: $102.70 | $0.00 |
DisclosureSEC source: 0001649094-24-000108 · wk-form4_1731117010.xml · derivative · entry 1 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,125 Underlying: Common Stock · 26,125 shares Expires 2034-11-06 F1 · derivative.exercise_date: As part of a company-wide grant to all eligible employees of the Issuer, on November 7, 2024 (the "Grant Date"), the Reporting Person was granted a performance stock option to purchase 26,125 shares of the Issuer's Common Stock at a per share exercise price of $102.70. The option is subject to (1) a service-based vesting condition (vesting as to one-third of the shares on each of the third, fourth and fifth anniversaries of the Grant Date) and (2) a performance-vesting condition (which generally requires that the trading price of the Issuer's Common Stock average, over a one-year period, is at least $154.05 (150% of the Grant Date closing price)). Read SEC document |
| November 05, 2024 Filed Nov 6, 2024 21:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $21.41 | $0.00 |
DisclosureSEC source: 0001649094-24-000099 · wk-form4_1730927624.xml · derivative · entry 6 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,497 Underlying: Common Stock · 5,000 shares Expires 2032-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. Read SEC document |
| November 05, 2024 Filed Nov 6, 2024 21:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,273 | $107.50 | $136,842.41 |
DisclosureSEC source: 0001649094-24-000099 · wk-form4_1730927624.xml · nonDerivative · entry 5 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,623 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $107.39 to $107.745. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 05, 2024 Filed Nov 6, 2024 21:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,524 | $106.82 | $162,787.58 |
DisclosureSEC source: 0001649094-24-000099 · wk-form4_1730927624.xml · nonDerivative · entry 4 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,896 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $106.38 to $107.28. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 05, 2024 Filed Nov 6, 2024 21:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,415 | $105.72 | $149,590.97 |
DisclosureSEC source: 0001649094-24-000099 · wk-form4_1730927624.xml · nonDerivative · entry 3 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,420 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $105.35 to $106.17. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 05, 2024 Filed Nov 6, 2024 21:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 788 | $104.80 | $82,582.40 |
DisclosureSEC source: 0001649094-24-000099 · wk-form4_1730927624.xml · nonDerivative · entry 2 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,835 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $104.345 to $105.33. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 05, 2024 Filed Nov 6, 2024 21:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 5,000 | $21.41 | $107,050.00 |
DisclosureSEC source: 0001649094-24-000099 · wk-form4_1730927624.xml · nonDerivative · entry 1 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 00:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $21.41 | $0.00 |
DisclosureSEC source: 0001649094-24-000079 · wk-form4_1728433783.xml · derivative · entry 7 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 169,497 Underlying: Common Stock · 5,000 shares Expires 2032-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 00:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 67 | $111.68 | $7,482.56 |
DisclosureSEC source: 0001649094-24-000079 · wk-form4_1728433783.xml · nonDerivative · entry 6 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,623 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 00:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 314 | $110.51 | $34,698.57 |
DisclosureSEC source: 0001649094-24-000079 · wk-form4_1728433783.xml · nonDerivative · entry 5 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,690 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $110.235 to $111.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 00:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,147 | $109.55 | $344,744.41 |
DisclosureSEC source: 0001649094-24-000079 · wk-form4_1728433783.xml · nonDerivative · entry 4 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,004 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $109.18 to $110.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 00:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 996 | $108.69 | $108,252.25 |
DisclosureSEC source: 0001649094-24-000079 · wk-form4_1728433783.xml · nonDerivative · entry 3 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,151 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $108.085 to $109.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 00:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 476 | $107.51 | $51,174.76 |
DisclosureSEC source: 0001649094-24-000079 · wk-form4_1728433783.xml · nonDerivative · entry 2 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,147 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $107.08 to $107.77. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 00:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 5,000 | $21.41 | $107,050.00 |
DisclosureSEC source: 0001649094-24-000079 · wk-form4_1728433783.xml · nonDerivative · entry 1 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 5,500 | $0.00 Strike: $21.41 | $0.00 |
DisclosureSEC source: 0001649094-24-000075 · wk-form4_1727986533.xml · derivative · entry 5 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 174,497 Underlying: Common Stock · 5,500 shares Expires 2032-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,030 | $115.01 | $118,462.36 |
DisclosureSEC source: 0001649094-24-000075 · wk-form4_1727986533.xml · nonDerivative · entry 4 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,623 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $114.95 to $115.16. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,056 | $114.37 | $349,511.66 |
DisclosureSEC source: 0001649094-24-000075 · wk-form4_1727986533.xml · nonDerivative · entry 3 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,653 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $113.83 to $114.82. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,414 | $113.38 | $160,320.73 |
DisclosureSEC source: 0001649094-24-000075 · wk-form4_1727986533.xml · nonDerivative · entry 2 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,709 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $112.795 to $113.73. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 5,500 | $21.41 | $117,755.00 |
DisclosureSEC source: 0001649094-24-000075 · wk-form4_1727986533.xml · nonDerivative · entry 1 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:13 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 1,667 | $0.00 Strike: $21.41 | $0.00 |
DisclosureSEC source: 0001649094-24-000062 · wk-form4_1725570829.xml · derivative · entry 10 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 179,997 Underlying: Common Stock · 1,667 shares Expires 2032-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:13 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 2,203 | $110.15 | $242,660.45 |
DisclosureSEC source: 0001649094-24-000062 · wk-form4_1725570829.xml · nonDerivative · entry 9 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,623 F5 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated September 4, 2024 were sold by the Reporting Person. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:13 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 80 | $117.28 | $9,382.40 |
DisclosureSEC source: 0001649094-24-000062 · wk-form4_1725570829.xml · nonDerivative · entry 8 Eydelman Mikhail · CIK 0001918033 · SVP, GEN COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,826 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.